What is Leerink Partnrs' Estimate for KROS FY2025 Earnings?

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Leerink Partnrs increased their FY2025 EPS estimates for shares of Keros Therapeutics in a report released on Tuesday, May 6th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of $0.94 for the year, up from their previous forecast of $0.87. The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share.

Other equities analysts have also issued reports about the company. Scotiabank decreased their target price on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a research report on Thursday, January 16th. Oppenheimer reduced their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research report on Thursday, January 16th. Wells Fargo & Company dropped their price objective on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, February 27th. Guggenheim reiterated a "neutral" rating on shares of Keros Therapeutics in a report on Friday, January 17th. Finally, Cantor Fitzgerald downgraded shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $38.67.

Keros Therapeutics Trading Down 0.6 %

KROS opened at $13.68 on Thursday. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $72.37. The firm has a 50-day moving average price of $12.10 and a two-hundred day moving average price of $25.34. The stock has a market capitalization of $555.64 million, a PE ratio of -2.63 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $3.63. The firm had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same period last year, the firm posted ($1.21) EPS.

Hedge Funds Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Braidwell LP raised its stake in Keros Therapeutics by 167.9% during the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company's stock worth $29,989,000 after acquiring an additional 1,187,199 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of Keros Therapeutics by 882.3% during the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company's stock worth $12,474,000 after buying an additional 1,099,519 shares in the last quarter. Lynx1 Capital Management LP bought a new position in shares of Keros Therapeutics in the 4th quarter valued at $8,612,000. Millennium Management LLC boosted its holdings in shares of Keros Therapeutics by 53.3% during the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company's stock valued at $13,901,000 after acquiring an additional 305,169 shares in the last quarter. Finally, Boxer Capital Management LLC acquired a new position in Keros Therapeutics in the 4th quarter worth about $3,958,000. Institutional investors own 71.56% of the company's stock.

Insider Activity at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was bought at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the acquisition, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. The trade was a 27.01 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 22.90% of the stock is currently owned by corporate insiders.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.